Amgen, a pioneer in innovative medicine, is on a mission to combat some of the most challenging diseases globally. With a focus on cancer, heart disease, osteoporosis, and inflammatory diseases, Amgen pushes boundaries in biotechnology, using cutting-edge technology and human genetic data to drive innovation. Recognized for its groundbreaking work, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company in 2024. Additionally, Forbes hailed Amgen as one of “America’s Best Large Employers.” As a member of the Dow Jones Industrial Average and the Nasdaq-100 Index, Amgen continues to lead the way in advancing healthcare solutions.
The recent ESMO results revealed by Amgen’s executive vice president, Jay Bradner, M.D., highlighted the company’s commitment to advancing diverse modalities for challenging cancers. These outcomes underscore Amgen’s leadership in oncology, showcasing significant advancements with both investigational and established therapies. With a profound knowledge of cancer biology and utilizing precise therapeutics, Amgen aims to target disease drivers with unparalleled precision.
Key presentations from the ESMO conference included:
- Initial results from the Phase 1b study of LUMAKRAS plus Vectibix in combination with FOLFIRI for first-line patients with KRAS G12C-mutated metastatic colorectal cancer.
- Phase 1 dose escalation and expansion data from AMG 193, featured in a presidential symposium session.
- First-in-human study of xaluritamig in men with metastatic castration-resistant prostate cancer.
Amgen’s abstracts covered a range of topics, from sotorasib plus panitumumab in colorectal cancer to fibroblast growth factor receptor 2 protein overexpression in advanced gastric or gastroesophageal cancer. The depth of research and innovation presented in these abstracts exemplifies Amgen’s dedication to improving patient outcomes and advancing the field of medicine.
Further information on these abstracts can be found in the detailed presentations at ESMO. Amgen’s ongoing commitment to research and development continues to drive progress in treating challenging diseases and improving the quality of life for patients worldwide.
Leave feedback about this